NYSE:ELAN - New York Stock Exchange, Inc. - US28414H1032 - Common Stock - Currency: USD
Taking everything into account, ELAN scores 5 out of 10 in our fundamental rating. ELAN was compared to 198 industry peers in the Pharmaceuticals industry. ELAN has only an average score on both its financial health and profitability. ELAN is not valued too expensively and it also shows a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 2.88% | ||
ROE | 5.87% | ||
ROIC | 1.42% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 5.4% | ||
PM (TTM) | 8.43% | ||
GM | 54.89% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.68 | ||
Debt/FCF | 13.2 | ||
Altman-Z | 0.97 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.71 | ||
Quick Ratio | 1.46 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 13.36 | ||
Fwd PE | 12.8 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 18.73 | ||
EV/EBITDA | 11.38 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NYSE:ELAN (5/23/2025, 12:03:48 PM)
12.56
-0.11 (-0.87%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 13.36 | ||
Fwd PE | 12.8 | ||
P/S | 1.41 | ||
P/FCF | 18.73 | ||
P/OCF | 11.66 | ||
P/B | 0.98 | ||
P/tB | N/A | ||
EV/EBITDA | 11.38 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 2.88% | ||
ROE | 5.87% | ||
ROCE | 2.05% | ||
ROIC | 1.42% | ||
ROICexc | 1.48% | ||
ROICexgc | 5.44% | ||
OM | 5.4% | ||
PM (TTM) | 8.43% | ||
GM | 54.89% | ||
FCFM | 7.52% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.68 | ||
Debt/FCF | 13.2 | ||
Debt/EBITDA | 4.86 | ||
Cap/Depr | 30.75% | ||
Cap/Sales | 4.56% | ||
Interest Coverage | 250 | ||
Cash Conversion | 59.71% | ||
Profit Quality | 89.28% | ||
Current Ratio | 2.71 | ||
Quick Ratio | 1.46 | ||
Altman-Z | 0.97 |